Cases of placental abruption included in our study will be clinically defined and will not be only diagnosed by histological examination.
All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis.

Placental Abruption

Placenta Diseases

CHRU de Brest (médecine interne)

Study on Retroplacental Hematomas in Finistère

Retrospective Descriptive Study on Retroplacental Hematomas in Finistère

presence of an histologic placental abruption

presence of thrombi in the chorionic plate or intervillous thrombi

presence of maternal vascular malperfusion lesions such as macroscopic or microscopic infarcts, decidual arteriopathy or abnormal villous maturation

presence of fetal vascular malperfusion signs such as obliterative fetal vasculopathy or avascular villi

presence of chorangiosis or erythroblastosis

presence of chronic inflammation such as villitis or chronic intervillositis of unknown etiology, chronic chorioamniotitis or chronic deciduitis

presence of acute inflammation such as acute chorioamniotitis or funiculitis

use of aspirin or heparin during pregnancy

occurrence of premature rupture of membrane

occurrence of disseminated intravascular coagulation

chronic hypertension or chronic nephropathy

University Hospital, Brest

Postpartum Hemorrhage

Postpartum Women

Postpartum Depression

Postpartum Stress

Postpartum Anxiety

The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.

• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.

The GAD-7 with a discrimination threshold ≥10.

Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46

• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46

The IES-R, validated in French, with a discrimination threshold ≥ 30.

EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)

CHU Clermont-Ferrand

Prevalence of Psychological Disorders After Immediate Postpartum Hemorrhage

the prevalence of depression, measured by the Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11

prevalence of depression among women with PPH between 500-1000 mL

The prevalence of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

severity of depression among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

severity of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

prevalence of anxiety and post-traumatic stress among women after an immediate PPH

prevalence of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

prevalence of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

severity of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

severity of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

University Hospital, Clermont-Ferrand

Phase 1 (run-in): Marevan®
Phase 2: Marevan®
Phase 3: generic warfarin #1
Phase 4: generic warfarin #2

Phase 1 (run-in): generic warfarin #1
Phase 2: generic warfarin #1
Phase 3: Marevan®
Phase 4: generic warfarin #2

Phase 1 (run-in): generic warfarin #1
Phase 2: generic warfarin #1
Phase 3: generic warfarin #2
Phase 4: Marevan®

Phase 1 (run-in): Marevan®
Phase 2: Marevan®
Phase 3: generic warfarin #2
Phase 4: generic warfarin #1

Phase 1 (run-in): generic warfarin #2
Phase 2: generic warfarin #2
Phase 3: Marevan®
Phase 4: generic warfarin #1

Phase 1 (run-in): generic warfarin #2
Phase 2: generic warfarin #2
Phase 3: generic warfarin #1
Phase 4: Marevan®

Atrial Fibrillation

Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.

Marevan®

Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.

generic warfarin #1

Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.

generic warfarin #2

Hospital São Paulo/Hospital Universitário da UNIFESP (University Hospital of UNIFESP)

Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

Therapeutic Equivalence Between Branded and Generic Warfarin Sodium Tablets in Adult Patients With Atrial Fibrillation in Brazil - Crossover Randomized Controlled Equivalence Trial

INR: International normalized ratio. INR will be assessed twice a month during the 16 weeks of study.
Delta INR will be calculated by the difference, in absolute numbers (i.e. in module), between the two valid INR measurements due for each patient with each formulation at each period. Difference between the delta INRs will be the outcome. We will compare generic to branded warfarin (Marevan®) and the generic formulations to each other.

INR: International normalized ratio. INR will be assessed twice a month during the 16 weeks of study.
We will calculate the mean INR for each formulation of warfarin; difference between the mean INRs will be the outcome. We will compare generic to branded warfarin (Marevan®) and the generic formulations to each other.

The warfarin dosage will be calculated as the sum of the dosage taken in the week before the study visit, as referred by the patient. We will calculate the mean dosage for each formulation of warfarin; difference between the mean dosage will be the outcome.
We will compare generic to branded warfarin (Marevan®) and the generic formulations to each other.

Includes ischemic stroke (differential diagnosis with hemorrhagic stroke by tomography) and thromboembolism of viscera or extremities (diagnosed by acute symptoms and relevant diagnostic tests).

Classified as major or minor bleeding events.
Major: intracranial hemorrhage, fatal bleeding, bleeding resulting in hemoglobin loss equal to or greater than 2.0 g / L, hemorrhage requiring transfusion, bleeding in sensitive areas such as the retina or pericardium.
Minor: all other bleeding.

TTR calculated by Rosendaal Method also known as linear interpolation method. We will calculate the mean TTR for each formulation of warfarin; difference between the mean TTRs will be the outcome.
We will compare generic to branded warfarin (Marevan®) and the generic formulations to each other.

cannabinoid/hemorrhage

Study on Retroplacental Hematomas in Finistère

Prevalence of Psychological Disorders After Immediate Postpartum Hemorrhage

Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

Dexanabinol in Severe Traumatic Brain Injury

The Maternal Lifestyle Study (MLS)

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi